Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism

Ranee Mehra, John Murren, Gina Chung, Brian Smith, Amanda Psyrri

Research output: Contribution to journalArticlepeer-review

Abstract

Irinotecan is an analogue of camptothecin, a topoisomerase I inhibitor, that has an important role in the management of advanced colorectal cancer. It is approved as first-line therapy in combination with 5-fluorouracil and leucovorin or as monotherapy in the second-line setting. Its clinical use has been associated with variability in terms of pharmacokinetic behavior and toxicities, especially myelosuppression and diarrhea. Irinotecan is metabolized to the active compound SN-38; it is now known that the metabolism of irinotecan and the inactivation of SN-38 by glucuronidation are mediated by genetic differences, which contributes to the variability. In this article, a case is presented that illustrates this, and there is a brief discussion of the clinical pharmacology of irinotecan and some of the genetic variations that affect its cellular metabolism.

Original languageEnglish (US)
Pages (from-to)61-64
Number of pages4
JournalClinical Colorectal Cancer
Volume5
Issue number1
DOIs
StatePublished - May 2005

Keywords

  • Absolute neutrophil count
  • Area under the curve
  • Bilirubin
  • Liver function tests

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism'. Together they form a unique fingerprint.

Cite this